CCN6 and breast cancer: It was reported that WISP3 was downregulated in 80% of the aggressive inflammatory breast cancers with high metastatic potential.15 Low CCN6 protein levels were associated with upregulated expression of phospho‐Akt‐1 (Ser473) expression in 21% of invasive breast carcinomas.30 Mammary epithelial cell‐specific ccn6 (WISP3) knockout mice develop invasive high‐grade mammary carcinomas,31 suggesting CCN6 as a tumour suppressor in breast cancer.